Literature DB >> 28411519

'Breaking Good News': Neurologists' experiences of discussing SUDEP with patients in Scotland.

Tom Nisbet1, Sue Turbull2, Sharon Mulhern3, Saif Razvi4.   

Abstract

Since the findings of a Fatal Accident Inquiry (FAI) in 2010, clinicians working in Scotland have been advised to discuss the risk of Sudden Unexpected Death in Epilepsy (SUDEP) with patients immediately or soon after a diagnosis of epilepsy is made. A thematic analysis was used to describe the experiences discussing SUDEP of 10 clinicians (six Consultant Neurologists and four Neurology Registrars) working in Scotland. Contrary to previous research, clinicians appear to be routinely discussing SUDEP in a standardized fashion with newly diagnosed patients and the FAI appears to have instigated this change in practice. Clinicians are ambivalent about the practice and whether this is a Breaking Bad News (BBN) experience. Clinicians appear to anticipate that patients will be anxious or distressed discussing SUDEP, despite their experiences that patients do not react this way. There are further concerns that the pressure to discuss SUDEP, as a result of the FAI, hinders effective communication of the SUDEP message. Implications for guideline development are discussed.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breaking Bad News; Epilepsy; Neurology practice; Qualitative; SUDEP; Thematic analysis

Mesh:

Year:  2017        PMID: 28411519     DOI: 10.1016/j.yebeh.2017.02.024

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  2 in total

Review 1.  Review: The past, present and future challenges in epilepsy-related and sudden deaths and biobanking.

Authors:  M Thom; M Boldrini; E Bundock; M N Sheppard; O Devinsky
Journal:  Neuropathol Appl Neurobiol       Date:  2018-02       Impact factor: 8.090

Review 2.  Let's talk SUDEP.

Authors:  Ayşe Deniz Elmali; Nerses Bebek; Betül Baykan
Journal:  Noro Psikiyatr Ars       Date:  2019-09-05       Impact factor: 1.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.